KNSA Q4 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M+230.1% YoY

Gross Profit

$48M77.0% margin

Operating Income

$6M9.8% margin

Net Income

$4M7.2% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-37.6%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$460M

Total Liabilities

$64M

Stockholders' Equity

$396M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$19M	+230.1%
Gross Profit	$48M	$15M	+220.3%
Operating Income	$6M	-$36M	+116.7%
Net Income	$4M	-$36M	+112.3%

Revenue Segments

Product

$40M65%

Collaboration

$22M35%